sexual
transmit
infect
sti
signific
contributor
global
burden
public
health
medic
care
sti
caus
sever
fetal
neonat
death
ectop
pregnanc
infertil
genit
neoplasia
despit
lead
sever
complic
clinic
public
health
practic
sometim
underestim
import
diagnos
sti
moreov
scientif
research
sti
remain
neglect
mani
sti
often
asymptomat
earli
infect
stage
increas
risk
unrecogn
world
health
organ
estim
approxim
million
new
infect
curabl
sti
occur
year
throughout
world
http
sti
caus
differ
microb
includ
bacteria
virus
protozoa
unfortun
infect
differ
sexual
transmit
pathogen
often
present
similar
clinic
symptom
almost
imposs
distinguish
therefor
import
develop
sensit
multitarget
highthroughput
method
detect
variou
agent
respons
sti
addit
rapid
accur
identif
critic
prevent
onward
transmiss
offer
immedi
intervent
adopt
earli
treatment
reduc
patient
manag
convent
diagnost
algorithm
sti
includ
cell
cultur
microscop
examin
enzym
immunoassay
serolog
investig
diagnosi
sti
cultur
serolog
remain
especi
herp
simplex
viru
treponema
pallidum
detect
cell
cultur
show
lowsensit
long
turnaround
time
make
assay
clinic
howev
past
two
decad
molecular
test
wide
use
detect
pathogen
associ
sti
compar
tradit
method
molecular
test
pcr
realtim
pcr
multiplex
pcr
microarray
rapid
turnaround
time
superior
sever
commerci
kit
system
base
nucleic
acid
amplif
develop
detect
pathogen
respons
system
still
disadvantag
high
cost
low
sampl
throughput
limit
number
pathogen
detect
singl
test
studi
massarray
system
agena
bioscienc
inc
san
diego
ca
usa
detect
platform
combin
endpoint
multiplexpcr
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
ms
util
develop
sexual
transmit
infect
assay
stim
simultan
detect
identifi
common
clinic
pathogen
implic
sti
includ
herp
simplex
viru
type
neisseria
gonorrhoea
chlamydia
trachomati
treponema
pallidum
trichomona
vaginali
mycoplasma
genitalium
haemophilu
ducreyi
three
controversi
microorgan
mycoplasma
homini
ureaplasma
urealyticum
ureaplasma
parvum
still
conclus
evid
whether
agent
consid
pathogen
also
includ
panel
studi
system
come
consider
benefit
multiplex
high
throughput
appli
success
detect
confirm
variou
kind
microorgan
includ
stim
assay
two
differ
gene
select
target
either
gene
detect
correspond
organ
posit
strategi
avoid
falseneg
result
thu
make
method
sensit
comprehens
perform
stim
evalu
use
clinic
specimen
patient
sexual
transmit
infect
stim
result
confirm
realtim
pcr
nest
pcr
discord
result
arbitr
ultrasensit
digit
pcr
method
initi
evalu
stim
assay
includ
archiv
dna
sampl
anal
swab
obtain
men
sex
men
msm
attend
local
clinic
test
posit
hiv
suscept
symptom
sti
detail
recruit
method
sampl
collect
data
collect
previous
evalu
clinic
perform
assay
clinic
specimen
urethralcerv
swab
urin
collect
shenzhen
center
chronic
diseas
control
dna
extract
clinic
specimen
perform
magna
pure
lc
instrument
use
magna
pure
lc
dna
isol
kit
roch
diagnost
mannheim
germani
candid
assay
target
highli
conserv
genom
region
eleven
agent
interest
identifi
chosen
basi
publish
valid
data
report
use
success
pcr
target
avoid
falseneg
result
two
target
agent
use
stim
method
human
hbb
gene
select
intern
control
therefor
develop
method
identifi
eight
etiolog
agent
relat
sti
three
controversi
organ
studi
ncbi
genbank
databas
http
wwwncbinlmnihgovgenbank
use
download
avail
full
partial
nucleic
acid
sequenc
target
primer
pair
multiplex
pcr
extens
probe
design
use
assay
design
softwar
agena
bioscienc
inc
san
diego
ca
usa
specif
confirm
primer
nucleotid
blast
tool
ncbi
http
wwwncbinlmnihgovtoolsprimerblast
everi
pcr
primer
includ
univers
tag
increas
molecular
weight
pcr
primer
extens
probe
obtain
tsingk
biotechnolog
beij
china
final
target
region
primersprob
stim
assay
list
tabl
supplementari
materi
multiplex
pcr
reaction
compos
dna
templat
pcr
buffer
agena
bioscienc
inc
mm
dntp
datp
dutp
dctp
dgtp
promega
madison
wi
usa
primer
mix
dna
polymeras
enzym
roch
molecular
system
inc
pleasanton
ca
usa
uracildna
glycosylas
shinegen
molecular
biotechnolog
shanghai
china
multiplex
pcr
amplif
perform
proflex
pcr
system
appli
bioscienc
foster
citi
ca
usa
use
pcr
plate
follow
thermocycl
program
use
pcr
min
min
initi
denatur
min
cycl
min
final
step
min
pcr
amplif
u
shrimp
alkalin
phosphatas
sap
ad
incub
min
min
remov
residu
dntp
singlebas
extens
sbe
reaction
perform
iplex
pro
reagent
kit
agena
bioscienc
inc
total
reaction
volum
sbe
reaction
termin
mix
iplex
pro
buffer
extens
probe
cocktail
thermosequenas
enzym
mix
product
sap
treatment
use
thermocycl
condit
cycl
cycl
final
min
sbe
reaction
probe
extend
one
massmodifi
nucleotid
depend
nucleotid
posit
interest
product
sbe
reaction
desalt
rotat
cation
ion
exchang
resin
agena
bioscienc
inc
min
purifi
product
spot
onto
spectrochip
ii
agena
bioscienc
inc
use
nanodispens
rs
equip
agena
bioscienc
inc
scan
use
mass
spectrometri
massarray
system
result
analyz
typer
softwar
version
agena
bioscienc
inc
confirm
posit
result
obtain
stim
assay
nucleic
acid
extract
use
stim
analysi
also
analyz
either
realtim
pcr
nest
pcr
posit
specimen
first
analyz
use
realtim
pcr
target
speciesspecif
gene
realtim
pcr
perform
use
simplex
realtim
pcr
develop
adapt
follow
organ
c
trachomati
pallidum
n
gonorrhoea
genitalium
homini
u
urealyticum
u
parvum
specimen
cycl
threshold
ct
valu
consid
neg
sampl
confirm
initi
round
realtim
pcr
analysi
retest
nest
pcr
primer
employ
nest
pcr
sequenc
design
inhous
select
accord
previous
publish
neg
control
includ
pcr
run
ensur
puriti
reagent
specimen
consid
posit
given
result
either
two
assay
result
posit
tabl
provid
detail
primer
probe
use
studi
realtim
pcr
nest
pcrbase
confirm
digit
pcr
dpcr
perform
arbitr
discrep
result
stim
assay
confirmatori
test
digit
pcr
amplif
carri
microchip
use
digit
pcr
system
appli
bioscienc
foster
citi
ca
usa
final
reaction
volum
prepar
contain
digit
pcr
master
mix
probe
primer
dna
templat
accord
manufactur
instruct
reaction
mixtur
immedi
load
dpcr
chip
use
digit
pcr
chip
loader
chip
place
proflex
pcr
system
pcr
amplif
use
follow
cycl
condit
initi
hold
min
cycl
min
min
follow
amplif
chip
insert
chip
reader
imag
data
analyz
use
cloudbas
analysissuit
softwar
digit
pcr
run
least
one
posit
neg
control
includ
differ
concord
rate
among
singl
infect
multipl
infect
specimen
compar
use
test
statist
analysi
carri
use
spss
softwar
version
spss
inc
chicago
il
usa
pvalu
consid
signific
comparison
diagnost
perform
stim
assay
monoplex
realtim
pcr
assess
measur
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
use
vassarstat
websit
http
vassarstatsnet
experi
perform
accord
ethic
standard
nation
research
committe
helsinki
declar
scientif
approv
conduct
studi
obtain
institut
review
board
institut
pathogen
biolog
written
inform
consent
obtain
everi
particip
interview
test
studi
develop
test
method
target
eleven
differ
etiolog
agent
simultan
identifi
common
pathogen
relat
sti
use
hbb
intern
control
nucleic
acid
extract
sampl
first
step
stim
assay
multiplex
pcr
use
specif
primer
probe
amplifi
highli
conserv
region
microbi
genom
second
step
stim
assay
involv
detect
specif
product
use
malditof
mass
spectromet
system
mass
product
measur
microorgan
specimen
determin
observ
base
composit
observ
avoid
falseneg
result
two
target
agent
use
stim
assay
result
nucleotid
blastn
analysi
show
test
primer
probe
work
well
result
reveal
develop
stim
method
satisfactori
analyt
specif
multiplex
detect
capac
target
organ
specif
detect
power
assay
evalu
use
nucleic
acid
extract
confirm
clinic
isol
sampl
tabl
posit
clinic
sampl
isol
h
ducreyi
obtain
posit
plasmid
target
gene
use
valid
specif
studi
result
show
stim
approach
accur
identifi
target
agent
posit
result
obtain
neg
control
figur
supplementari
materi
evalu
detect
specif
crossreact
genet
clinic
nonspecif
pathogen
test
use
assay
procedur
use
sti
detect
assay
result
neg
nonspecif
posit
reaction
observ
analyt
sensit
limit
detect
stim
assay
develop
studi
determin
test
serial
dilut
posit
standard
rang
plasmid
carri
target
gene
agent
regress
probit
analysi
carri
use
spss
statist
calcul
limit
detect
lod
assay
could
measur
probabl
probit
analysi
four
run
replic
dilut
differ
plasmid
concentr
gave
lod
rang
copiesreact
tabl
evalu
perform
simultan
detect
system
clinic
sampl
screen
total
anal
swab
obtain
msm
use
develop
stim
assay
among
archiv
dna
sampl
posit
stim
method
least
one
microorgan
etiolog
agent
detect
sampl
method
allow
diagnosi
bacteri
organ
specimen
viral
organ
specimen
combin
specimen
sixtyseven
specimen
also
identifi
mix
agent
combin
stim
assay
target
organ
furthermor
multipl
combin
sampl
test
sampl
total
identifi
dualcombin
microorgan
analyz
sampl
total
found
detect
agent
organ
belong
stim
assay
detect
survey
sampl
posit
specimen
stim
method
result
confirm
use
relat
confirmatori
test
sampl
found
posit
singl
microorgan
stim
sampl
also
posit
singl
organ
initi
realtim
pcr
assay
target
speciesspecif
gene
howev
multipl
agent
combin
specimen
total
posit
specimen
show
result
concord
stim
assay
discord
specimen
verifi
nest
pcr
bidirect
sequenc
combin
result
two
confirmatori
test
concord
rate
singl
organ
multipl
agent
combin
forti
stimsposit
specimen
confirm
either
realtim
pcr
nest
pcr
analysi
specimen
yield
discrep
result
develop
stim
assay
confirmatori
test
ultrasensit
digit
pcr
perform
among
stimsposit
confirmatori
testneg
sampl
confirm
posit
digit
pcr
assay
wherea
remain
unverifi
resolut
discord
result
includ
singl
organ
sampl
multipl
agent
combin
sampl
tabl
result
confirmatori
test
arbitr
test
reveal
retest
specimen
verifi
posit
either
test
inde
accur
posit
irrespect
classif
neg
either
assay
arbitr
test
result
illustr
tabl
figur
supplement
materi
tabl
show
perform
stim
assay
well
resolut
discord
result
arbitr
test
overal
verif
rate
singl
organ
wherea
rate
multipl
agent
combin
differ
signific
among
two
rate
p
test
verif
rate
target
organ
stim
assay
rang
minimum
n
gonorrhoea
maximum
u
parvum
pallidum
genitalium
among
specimen
test
major
screen
sampl
detect
posit
u
urealyticum
follow
c
trachomati
homini
vaginali
h
ducreyi
detect
studi
sampl
multipl
combin
includ
u
urealyticum
homini
frequent
type
multipl
combin
detect
survey
sampl
u
urealyticum
c
trachomati
homini
number
test
specimen
multipl
combin
shown
tabl
evalu
clinic
perform
assay
clinic
specimen
urethralcerv
swab
urin
test
parallel
use
stim
assay
monoplex
realtim
pcr
agent
primer
probe
use
monoplex
realtim
pcr
list
tabl
supplementari
materi
perform
characterist
sensit
specif
ppv
npv
microorgan
differ
specimen
type
calcul
list
tabl
overal
good
sensit
rang
specif
rang
npv
rang
evalu
target
stim
lower
lod
realtim
pcr
result
show
expand
ppv
rang
term
differ
agent
specimen
type
tabl
work
detail
design
develop
stim
assay
use
clinic
sampl
screen
eleven
sexual
transmit
microorgan
sti
compris
number
fatal
often
seriou
infect
yet
infect
often
pose
challeng
identifi
caus
organ
rapid
accur
identif
sexual
transmit
infect
reduc
onward
transmiss
improv
treatment
efficaci
mani
pathogen
respons
sti
identifi
cell
cultur
microscop
examin
antigen
detect
pcrbase
approach
shown
sensit
detect
pathogen
clinic
sampl
tradit
diagnost
test
ie
cultur
microscopi
antigen
detect
sampl
collect
appropri
time
consid
wide
rang
etiolog
agent
caus
sti
similar
clinic
present
infect
produc
differ
pathogen
multiplex
molecular
diagnost
tool
seem
optim
method
rapid
therefor
util
multiplex
pcr
malditof
ms
incorpor
stim
assay
might
help
better
understand
phenomenon
mix
infect
clinic
specimen
sever
complex
sti
feasibl
effect
screen
approach
essenti
time
implement
effect
infect
control
measur
prevent
transmiss
addit
increas
antimicrobi
drug
resist
n
gonorrhoea
genitalium
remain
import
largescal
epidemiolog
studi
surveil
program
need
determin
optim
prevent
strategi
reduc
global
burden
sti
routin
screen
pathogen
associ
sti
annual
basi
recommend
pregnant
women
sexual
activ
femal
year
age
atrisk
date
nucleic
acid
amplif
test
naat
accept
worldwid
import
method
screen
caus
agent
sti
sever
approv
commerci
molecular
panel
addit
sever
emerg
nucleic
acid
amplif
platform
combin
fulli
partial
autom
instrument
avail
target
multipl
microorgan
singl
test
howev
platform
low
throughput
high
cost
per
sampl
prevent
rapid
screen
larg
number
specimen
compar
diagnost
strategi
stim
use
malditof
ms
technolog
gener
reliabl
easili
autom
stim
assay
simultan
detect
nucleic
acid
protozoan
viral
bacteri
organ
analyz
approxim
clinic
sampl
within
work
day
high
sampl
throughput
method
cost
detect
pathogen
use
stim
less
includ
cost
nucleic
acid
extract
therefor
stim
method
great
potenti
appli
largescal
epidemiolog
program
specif
microorgan
sti
provid
import
inform
public
health
intervent
diseas
control
erad
one
main
challeng
design
establish
assay
limit
potenti
crossreact
organ
particularli
commens
speci
exampl
test
site
includ
adequ
number
commonli
neisseria
meningitidi
commens
neisseria
speci
caus
crossreact
screen
assay
due
high
degre
nucleic
acid
homolog
n
among
target
use
identifi
c
trachomati
cryptic
plasmid
wide
use
howev
subsequ
shown
sequenc
variat
cryptic
plasmid
detect
sever
demonstr
falseneg
result
may
occur
cryptic
plasmid
use
alon
target
detect
c
trachomati
particularli
screen
clinic
sampl
region
previous
sever
commerci
naat
use
singl
target
pathogen
associ
sexual
transmit
infect
led
emerg
falseneg
diagnost
result
infect
went
untreat
transmit
individu
without
knowledg
overcom
potenti
problem
stim
assay
use
two
target
pathogen
increas
sensit
specif
reduc
falseneg
result
result
studi
shown
stim
method
use
detect
sever
microorgan
simultan
high
specif
accuraci
anoth
aspect
could
affect
perform
assay
qualiti
sampl
term
etiolog
load
number
copi
contain
pathogen
studi
posit
specimen
use
develop
stim
assay
confirm
confirmatori
test
one
possibl
caus
higher
number
discrep
clinic
specimen
caus
agent
sti
may
due
target
pathogen
low
concentr
report
van
et
al
evalu
bd
max
digit
pcr
success
appli
field
pathogen
particularli
suit
lowlevel
detect
nucleic
acid
even
highli
complex
arbitr
stage
ultrasensit
digit
pcr
perform
resolv
discord
result
thirtyon
specimen
confirm
posit
arbitr
test
significantli
shorten
detect
time
ultrasensit
diagnosi
method
sti
requir
detect
extrem
small
amount
microorgan
directli
without
cultur
specimen
base
sensit
test
lod
stim
assay
reach
minimum
copi
per
reaction
moreov
subsequ
verifi
method
also
high
sensit
evalu
clinic
sampl
thu
target
pathogen
low
concentr
clinic
specimen
stim
assay
substanti
increas
abil
detect
potenti
pathogen
increas
likelihood
accur
diagnosi
miss
msm
risk
acquir
protozoan
viral
bacteri
sti
male
femal
partner
previou
studi
shown
preval
sti
rang
studi
indic
detect
rate
agent
among
msm
higher
data
studi
specul
differ
caus
improv
coverag
screen
use
method
coinfect
frequent
encount
among
msm
present
difficult
diagnost
challeng
clinic
microbiolog
laboratori
studi
specimen
identifi
mix
agent
combin
multipl
combin
includ
u
urealyticum
homini
find
consist
recent
report
studi
use
commerci
detect
high
detect
rate
u
urealyticum
homini
might
caus
infect
commens
role
pathogen
howev
earlier
studi
suggest
u
urealyticum
homini
combin
may
associ
increas
drug
detect
sti
use
stim
approach
might
help
time
discoveri
mix
agent
combin
clinician
could
prescrib
appropri
antibiot
patient
accord
result
identifi
pathogen
howev
limit
exist
stim
assay
mention
previou
first
load
organ
low
stim
assay
may
fail
detect
target
pathogen
volum
specimen
use
initi
pcr
second
high
cost
equip
larg
footprint
system
limit
applic
rang
mass
spectromet
platform
clinic
laboratori
third
nearli
hour
turnaround
time
stim
assay
suitabl
detect
small
number
sampl
addit
anal
swab
use
evalu
stage
archiv
dna
sampl
limit
sampl
volum
prevent
us
test
parallel
use
stim
assay
monoplex
realtim
pcr
agent
therefor
addit
test
differ
sampl
type
includ
anal
swab
requir
futur
evalu
comprehens
perform
stim
assay
final
posit
clinic
sampl
isol
h
ducreyi
avail
specif
h
ducreyi
determin
analysi
plasmid
contain
respect
target
sequenc
given
rapid
sensit
specif
stim
use
highthroughput
screen
tool
detect
mix
infect
sti
great
potenti
largescal
sti
epidemiolog
program
